Navigation Links
STAAR Surgical Reports Third Quarter Results

International Sales Grow 17% Year-Over-Year; Including 45% Refractive


Cash Used For Operations Reduced By 54% Compared With Q207

Gross Margin Expands 2.1% Year-Over-Year to 49.7%

MONROVIA, Calif., Oct. 30 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced financial results for its third quarter ended September 28, 2007.

Total product sales for the third quarter were $13,629,000, an increase of 2.4% compared with $13,313,000 reported for the same period of 2006. The year-over-year increase in sales during the third quarter of 2007 was the result of increased international sales, which grew 17% compared with the third quarter of 2006. Global cataract sales in the third quarter of 2007 declined by 1.5% compared with the same quarter of 2006, while total refractive sales grew 17.1%. The favorable impact of changes in currency on third quarter 2007 sales was approximately $471,000.

For the first nine months of 2007, total product sales were $43,478,000, an increase of 4.7% compared with the same period of last year. The increase in sales during the first nine months of 2007 was also led by strong international product sales, which grew 16.6% during this period. The favorable impact of changes in currency on sales in the first nine months of 2007 was approximately $1,462,000.

International sales for the third quarter of 2007 were $8,890,000, up 16.9% compared with $7,608,000 reported in the same period of last year. Third quarter international refractive sales were $2,290,000, up 44.9% compared with the third quardensed Consolidated Balance Sheet

(in 000's)


September 28, December 29,

2007 2006

Cash and cash equivalents $14,196 $7,758

Short-term investments-restricted $150 $-

Accounts receivable, net 5,961 6,524

Inventories, net 13,789 12,939

Prepaids, deposits, and other current assets 2,614 1,923

Total current assets 36,710 29,144

Investment in joint venture - 397

Property, plant, and equipment, net 5,598 5,846

Patents and licenses, net 4,079 4,439

Goodwill, net 7,534 7,534

Long-term investments-restricted - 150

Other assets 256 260

Total assets $54,177 $47,770

Notes payable-Line of Credit $- $1,802

Accounts payable 4,572 5,055

Other current liabilities 9,074 8,074

Total current liabilities 13,646 14,931

Other-long term liabilities 1,305 1,079

Warrant Obligation 102 -

Total liabilities 15,053 16,010

Stockholders' equity - net 39,124 31,760

Total liabilities, warrant obligation

and equity $54,177 $47,770

STAAR Surgical Company

Condensed Consolidated Statements of Cash Flows

(in 000's)


Nine Months Ended

September September

28 29,

2007 2006

Cash flows from operating


Net loss $(11,708) $(9,369)

Adjustments to reconcile net loss

to net cash used in operating


Depreciation of property, plant

and equipment 1,465 1,391

Amortization of intangibles 360 361

Amortization of note discount 17 -

Loss on extinguishment of debt 272 -

Fair value adjustment of warrant

obligation (148) -

Loss on disposal of fixed assets 191 144

Equity in operations of joint

venture 280 24

Stock-based compensation 1,098 1,333

Note receivable reserve

(reversal) charge - (331)

Other 107 (44)

Changes in working capital:

Accounts receivable 456 (1,296)

Inventories (728) 946

Prepaids, deposits and other

current assets (894) (806)

Accounts payable (382) 168

Other current liabilities 685 243

Net cash used in operating

activities (8,929) (7,236)

Cash flows from investing activities:

Acquisition of property, plant

and equipment (379) (747)

Proceeds from sale lease back of

property, plant and equipment - 271

Purchase of short-term

investments - (193)

Dividend received from joint

venture 117 43

(Increase) decrease in other

assets 4 (111)

Proceeds from notes receivable

and other - 311

Net cash (used in)

provided by investing

activities (258) (426)

Cash flows from financing


Borrowings under line of credit 1,812 1,786

Repayment of line of credit (3,610) (1,676)

Repayment of lease lines of

credit (429) (66)

Proceeds from note payable 4,000 -

Repayment of note payable (4,000) -

Net proceeds from private

placement 16,613 -

Proceeds from the exercise of

stock options 584 2,614

Net cash provided by

financing activities 14,970 2,658

Effect of exchange rate changes on

cash and cash equivalents 655 489

(Decrease) increase in cash and cash

equivalents 6,438 (4,515)

Cash and cash equivalents, at

beginning of the period 7,758 12,708

Cash and cash equivalents, at end of

the period $14,196 $8,193

ter of 2006. Third quarter cataract sales were $6,532,000, up 9.6% compared with the third quarter of 2006. International sales for the first nine months of 2007 were $28,487,000, up 16.6% compared with the same period of 2006.

"We have continued to achieve strong growth in both our cataract and refractive product categories in the international markets," said David Bailey, president and CEO of STAAR Surgical. "In cataract, we achieved 9.6% sales growth during the third quarter compared with last year, and significantly, this included 14.6% growth in Germany. In our international refractive franchise, we achieved 45% sales growth compared with the third quarter of 2006, which more than offset the challenges we faced in our U.S. refractive business and led to 17.1% overall growth in this product category. We believe we can continue to achieve strong growth in the international markets and are pursuing a number of strategic initiatives to support future opportunities including continued geographic expansion into high potential markets such as China, India and Japan.

"Our agreement to buy out the interests of all other shareholders in Canon Staar Co., Inc., our joint venture in Japan, underscores the international nature of our business and our commitment to exploiting opportunities where we have been most successful. The acquisition, announced last week, consolidates our intellectual property portfolio, especially in preloaded injectors where Canon Staar has demonstrated technological leadership.

"Declines in the U.S. market in the third quarter are partly a continuation of a long-term trend, but also reflect short-term disruption resulting from the radical steps we have taken in an effort to reverse the trend," continued Mr. Bailey. "In this last quarter, we implemented our strategy of developing separate sales forces for the cataract and refractive product lines. This change brings our U.S. marketing approach in line with our global approach, where separating the distribution of cataract and refractive products has been a key to success. In cataract, we were pleased to report that a majority of the long-term independent sales representatives whom we targeted to include in our renewed cataract sales force will continue to work with STAAR. This newly aligned team's focus on driving cataract sales growth in the U.S. will be critical as we near the launches of several new IOL product and injection systems throughout the remainder of 2007 and into 2008. They will also be in a position to capitalize on higher reimbursement rates for our aspheric lenses when we secure NTIOL status for the lenses.

"We have deployed our new U.S. refractive sales teams with a unified marketing approach and a consistent message," continued Mr. Bailey. "Our refractive sales force will operate in teams comprised solely of STAAR employees. Each of the six planned teams will be led by a sales manager and will also include a practice development specialist and a surgical proctor. To date, we have filled 15 out of the 18 sales team positions and expect to have the remaining positioned filled by the end of the year. While we expect this new structure to positively impact our financial results as early as the fourth quarter of 2007, we believe we will see the greatest impact, in the form of Visian ICL (TM) sales growth throughout 2008. In particular, our specialized sales force will assist our customers in identifying the patients most likely to benefit from the Visian ICL, which has been a gating factor for U.S. Visian ICL sales growth."

Total U.S. sales for the third quarter of 2007 were $4,739,000, down 16.9% compared with the same quarter of 2006. Third quarter U.S. refractive sales were $1,106,000, down 16.2% compared with $1,321,000 for the third quarter of 2006 and up 1.3% compared with $1,092,000 reported for the second quarter of 2007. Third quarter U.S. cataract sales were $3,567,000, down 16.8% compared with the same quarter of 2006.

Total U.S. sales during the first nine months of 2007 were $14,991,000, down 12.2% compared with $17,080,000 in the same period of 2006. U.S. refractive sales during the first nine months of 2007 were $3,276,000, down 4.6% compared with the same period of 2006.

Gross profit margin for the third quarter increased 2.1% to 49.7% compared with 47.6% in the third quarter of 2006 driven by an increase in high margin refractive sales in the product mix. This increase was partially offset by higher inventory reserve expense and manufacturing engineering costs. Gross profit margin in the second quarter of 2007 was 48.5%.

Selling, general, and administrative expenses for the third quarter of 2007 were $10,387,000, up 15.1% from $9,027,000 in expenses reported for the third quarter of 2006.

General and administrative expenses for the third quarter of 2007 were $2,868,000, up 8.7% compared with $2,598,000 in expenses reported for the third quarter of 2006. The increase in general and administrative expenses was primarily due to increased international travel associated with increased oversight of foreign subsidiaries and increased bank charges associated with the termination of the Wells Fargo credit line.

Marketing and selling expenses for the third quarter of 2007 increased 13.5% to $5,775,000 compared with $5,090,000 in the third quarter of 2006. The increase for the quarter is primarily due to increased salaries and expenses due to global headcount increases, the unfavorable effect of currencies on expenses partially offset by decreased U.S. sales commissions.

Research and development expenses for the third quarter of 2007 increased 4.4% to $1,743,000 compared with $1,670,000 reported for the third quarter of 2006. The increase is due to increased salaries and benefits and severance costs associated with our recent restructuring.

Other expense for the third quarter of 2007 was $409,000 compared with income of $105,000 reported for the third quarter of 2006. Other expense increased due to inventory reserves and sales allowances recorded by the Company's Japanese joint venture as a result of the distributor's decision to curtail distribution of one of the joint venture's products in favor of a full launch of the second generation alternative. Other expense also increased due to increased interest expense from capital lease transactions and foreign exchange losses recorded during the period. Other expense was partially offset by an increase in interest income and other miscellaneous income.

During the quarter the Company reached a settlement with the German Ministry of Finance related to taxes assessed in connection with unreported sales of a company controlled by the former President of Domilens that reduced the Ministry's original claim by two thirds. As a result of the settlement, the Company reversed approximately $460,000 in income tax expense originally recorded in the fourth quarter of 2006.

Net loss for the third quarter of 2007 was $3,830,000 or $0.13 per share. The Company reported a net loss of $2,789,000 or $0.11 per share for the third quarter of 2006, and a net loss of $4,357,000 or $0.16 per share for the second quarter of this year.

STAAR exited the third quarter with approximately $14,196,000 in cash and cash equivalents compared with $7,758,000 at the end of the fourth quarter of 2006. The Company used $1,965,000 in cash for operating activities, compared with $1,673,000 in the third quarter of 2006 and $4,238,000 in the second quarter of this year.

The Company took measures during the quarter aimed at reducing the global cash burn to approximately $2 million per quarter, and expects to manage the global cash burn to approximately this level for the foreseeable future. This objective does not include the effect or potential effect on cash of the recent acquisition of Canon's interest in the Japanese joint venture.

While STAAR will use preferred stock to pay for most of the Canon Staar buy-out, the purchase price also calls for $4 million in cash to be paid at closing. Closing will occur on December 28, 2007 or after all conditions to closing have been met. STAAR has sufficient cash reserves to pay the cash consideration, but prior to closing may elect to seek financing for the transaction and additional working capital purposes. Based on recent indications of interest, STAAR believes it could obtain such financing on reasonably acceptable terms should it choose to do so

Conference Call

The Company will host a conference call and webcast on Tuesday, October 30, 2007 at 5:00 p.m. Eastern Time to discuss the Company's third quarter and current corporate developments. The dial-in number for the conference call is 800-257-2182 for domestic participants and 303-262-2141 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, both using passcode 11099475#. To access the live webcast of the call, go to STAAR Surgical's website at An archived webcast will also be available at

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. More than 85,000 ICLs have been sold worldwide. More information is available at

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including any projections of earnings, revenue, sales, cash or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements regarding expectations for success of the ICL or other products in U.S. or international markets, any statements concerning the success of initiatives to restructure the U.S. sales force, pending transactions including our agreement to purchase the interests of all other shareholders of Canon Staar, the availability of financing , proposed new products, including the Toric ICL, and government approval of such products or services, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the challenge of restructuring our largely independent marketing model and developing a direct sales targeted at the refractive market, our ability to address FDA concerns over the clinical study for the Toric ICL and to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance, the challenge of managing foreign subsidiaries, the willingness of surgeons and patients to adopt a new product and procedure, and our ability to successfully market the ICL in the U.S. while overcoming the foregoing challenges. Our planned acquisition of the other shareholders' interests in Canon Staar is subject to numerous risks including contractual conditions to closing that may not be satisfied, our ability to successfully integrate the Canon Staar business or employees into its overall business and our limited access to information. Our financial condition can be adversely affected by general economic conditions, and other factors beyond our control, including those detailed from time to time in our reports filed with the Securities and Exchange Commission. STAAR assumes no obligation to update these forward- looking statements to reflect future events or actual outcomes and does not intend to do so.

CONTACT: Investors Media

EVC Group EVC Group

Douglas Sherk, 415-896-6820 Jennifer Saunders, 646-201-5431

Jennifer Beugelmans, 646-201-5447

STAAR Surgical Company

Condensed Consolidated Statements of Income

(In 000's except for per share data)


Three Months Ended Nine Months Ended

Sept. 28, Sept. 29, Sept. 28, Sept. 29,

2007 2006 2007 2006

Sales $13,629 $13,313 $43,478 $41,511

Cost of goods sold 6,859 6,980 22,176 21,859

Gross profit 6,770 6,333 21,302 19,652

General and administrative 2,868 2,598 9,581 8,135

Marketing and selling 5,775 5,090 17,223 15,610

Research and development 1,743 1,670 4,987 5,185

Other charges (331) (331)

Total selling, general and

administrative expenses: 10,387 9,027 31,791 28,599

Operating loss (3,617) (2,694) (10,489) (8,947)

Other expense, net (409) 104 (880) 99

Loss before income taxes (4,026) (2,590) (11,369) (8,848)

Income tax provision (195) 199 339 521

Net loss $(3,831) $(2,789) $(11,708) $(9,369)

Basic and diluted loss per share $(0.13) $(0.11) $(0.42) $(0.37)

Weighted average shares

outstanding 29,374 25,293 27,993 24,994

STAAR Surgical Company

Global Sales

(in 000's)


Three Months Ended Nine Months Ended

Sept. 28, Sept. 29, Sept. 28, Sept. 29,

Geographic Sales 2007 2006 %Change 2007 2006 %Change

United States $4,739 $5,705 -16.9% $14,991 $17,080 -12.2%

Germany 5,743 4,969 15.6% 17,471 15,491 12.8%

Other 3,147 2,639 19.2% 11,016 8,940 23.2%

Total Sales $13,629 $13,313 2.4% $43,478 $41,511 4.7%

Product Sales


IOLs $5,378 $6,067 -11.4% $17,564 $19,010 -7.6%

Other Cataract 4,722 4,182 12.9% 14,392 13,074 10.1%

Total Cataract 10,100 10,249 -1.5% 31,956 32,084 -0.4%


ICL/TICL 3,290 2,784 18.2% 10,729 8,437 27.2%

Other Refractive 106 117 -9.4% 330 487 -32.2%

Total Refractive 3,396 2,901 17.1% 11,059 8,924 23.9%

Glaucoma 133 163 -18.4% 463 503 -8.0%

Total Sales $13,629 $13,313 2.4% $43,478 $41,511 4.7%

STAAR Surgical Company


SOURCE STAAR Surgical Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indonesian boy with huge neck tumor was surgically removed
2. New spray gel heals surgical wounds
3. FDA approves surgical gel
4. Lower surgical volume linked to higher death rate
5. Sleep apnoea linked to surgical risks
6. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
7. Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer
8. Surgeon Attempts to Create A Surgical Hernia Feat
9. Researchers Aim To Develop Next Generation Of Surgical Robots
10. Arrow Embedded In Tribal’s Chest For Two Weeks Surgically Remove
11. Surgical Intervention to Solve Obesity and Related Problems
Post Your Comments:
(Date:11/29/2015)... San Jose, CA (PRWEB) , ... November 29, 2015 , ... ... Bay Area, is proud to announce their December, 2015, featured apartment community: Epic. In ... looking for corporate housing in the tight Bay Area rental market to efficiently find ...
(Date:11/28/2015)... ... 2015 , ... Safe storage for contraceptive devices may not always be easy ... Jersey and the other from Bradley Beach, New Jersey, there is an easy solution ... having to replace NuvaRings more often than necessary. As such, it affords peace of ...
(Date:11/28/2015)... ... , ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, ... of up to 20% off orders $80 or more to free gifts with purchases, there ... , As a competitive e-commerce website for skin care and cosmetic needs, customers will save ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
Breaking Medicine Technology: